78
Participants
Start Date
October 12, 2020
Primary Completion Date
June 3, 2024
Study Completion Date
June 3, 2024
Sym021
IV infusion over 30 minutes on day 1 and 15 of each cycle.
Sym022
IV infusion over 30 minutes on day 1 and 15 of each cycle.
Sym023
IV infusion over 30 minutes on day 1 and 15 of each cycle.
Irinotecan Hydrochloride
IV infusion over 90 min on day 1 and 15 of the first 2 cycles. After 2 cycles of treatment, irinotecan may be discontinued at the Investigator's discretion
Mount Sinai - PRIME, New York
Montefiore Medical Center PRIME, The Bronx
Centre Georges-François Leclerc, Department of Medical Oncology, Dijon
Virginia Cancer Specialists, PC, Fairfax
Hospital Universitario San Carlos, Madrid
Mayo Clinic - Jacksonville, Jacksonville
Moffitt Cancer Center, Tampa
Institut de Cancerologie de L'Ouest, Saint-Herblain
University of Cincinnati Medical Center, Cincinnati
START Midwest, Grand Rapids
Mayo Clinic, Rochester
University of Kansas Medical Center (KUMC), Westwood
MD Anderson, Houston
University of Colorado, Aurora
University of Chicago, Chicago
Princess Margaret Cancer Centre, Toronto
Vall d'Hebron Institute of Oncology, Barcelona
Symphogen A/S
INDUSTRY